ALNY

250.59

0.16% -0.41

Handel nachbörslich: 250.59

Alnylam Pharmaceuticals Inc (ALNY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALNY? Forum Prognose

Schlusskurs vom Vortag:

$251.00

Offen:

$253.7

24-Stunden-Volumen:

645.36K

Relative Volume:

0.97

Marktkapitalisierung:

$32.44B

Einnahmen:

$2.25B

Nettoeinkommen (Verlust:

$-278.16M

KGV:

-115.48

EPS:

-2.17

Netto-Cashflow:

$-42.59M

1W Leistung:

-2.29%

1M Leistung:

-5.43%

6M Leistung:

-10.24%

1J Leistung:

+61.94%

1-Tages-Spanne:

$246.85

$253.70

1-Wochen-Bereich:

$246.61

$260.00

52-Wochen-Spanne:

$141.97

$304.39

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Firmenname

Alnylam Pharmaceuticals Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

(617) 551-8200

Adresse

675 WEST KENDALL STREET, CAMBRIDGE, MA

Mitarbeiter

2,230

Twitter

@alnylam

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

ALNY's Discussions on Twitter

Vergleichen Sie ALNY mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-12	Herabstufung	Wolfe Research	Peer Perform → Underperform
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-08-16	Hochstufung	Goldman	Neutral → Buy
2024-02-16	Herabstufung	Goldman	Buy → Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-12-08	Eingeleitet	Wells Fargo	Equal Weight
2023-10-11	Herabstufung	Oppenheimer	Outperform → Perform
2023-09-29	Eingeleitet	Raymond James	Outperform
2023-05-05	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-04-26	Eingeleitet	SMBC Nikko	Neutral
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-01-18	Eingeleitet	Canaccord Genuity	Buy
2022-09-09	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-27	Herabstufung	Guggenheim	Buy → Neutral
2022-06-07	Eingeleitet	William Blair	Outperform
2022-04-25	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-03-01	Eingeleitet	Citigroup	Buy
2022-02-03	Hochstufung	Guggenheim	Neutral → Buy
2022-01-03	Hochstufung	Piper Sandler	Neutral → Overweight
2021-11-22	Hochstufung	Goldman	Neutral → Buy
2021-11-22	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-11-01	Hochstufung	Oppenheimer	Perform → Outperform
2021-10-04	Hochstufung	UBS	Neutral → Buy
2021-08-04	Herabstufung	Piper Sandler	Overweight → Neutral
2021-02-22	Herabstufung	Guggenheim	Buy → Neutral
2021-02-12	Herabstufung	Citigroup	Buy → Neutral
2021-02-12	Bestätigt	H.C. Wainwright	Buy
2021-01-25	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2020-09-30	Fortgesetzt	Berenberg	Hold
2020-09-08	Eingeleitet	Citigroup	Buy
2020-08-11	Herabstufung	Oppenheimer	Outperform → Perform
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2020-05-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-04-24	Fortgesetzt	Evercore ISI	Outperform
2020-03-19	Eingeleitet	Berenberg	Buy
2019-12-19	Bestätigt	Chardan Capital Markets	Buy
2019-11-20	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-05-23	Fortgesetzt	Goldman	Neutral
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-03-06	Hochstufung	Evercore ISI	In-line → Outperform
2019-03-05	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-01-23	Eingeleitet	UBS	Neutral
2018-10-01	Eingeleitet	Cantor Fitzgerald	Overweight
2018-08-13	Bestätigt	Stifel	Buy
2018-08-07	Hochstufung	Stifel	Hold → Buy
2018-05-04	Bestätigt	Stifel	Hold
2018-03-28	Eingeleitet	Evercore ISI	In-line

Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

11:58 AM

BridgeBio’s Attruby Off To A Strong Start – But Alnylam Awaits - News & Insights

11:58 AM

04:49 AM

Ieq Capital LLC Acquires 34,613 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

04:49 AM

03:35 AM

Vontobel Holding Ltd. Has $424,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

03:35 AM

Feb 20, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update - MarketBeat

Feb 20, 2025

Rhumbline Advisers Sells 1,850 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Feb 20, 2025

Baillie Gifford & Co. Sells 846,741 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Feb 20, 2025

BridgeBio: Strong Start For Attruby (NASDAQ:BBIO) - Seeking Alpha

Feb 20, 2025

Biotech Stocks Facing FDA Decision In March 2025 - RTTNews

Feb 20, 2025

Feb 19, 2025

Strategic Financial Concepts LLC Purchases Shares of 176,485 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Feb 19, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells $169,204.23 in Stock - MarketBeat

Feb 19, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,561 Shares - MarketBeat

Feb 19, 2025

Jeffrey V. Poulton Sells 967 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock - MarketBeat

Feb 19, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 1,440 Shares - MarketBeat

Feb 19, 2025

Canaccord Genuity Group Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat

Feb 19, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Asset Management One Co. Ltd. - MarketBeat

Feb 19, 2025

Feb 18, 2025

Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight - GlobeNewswire Inc.

Feb 18, 2025

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Feb 18, 2025

Scotiabank Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat

Feb 18, 2025

Feb 17, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Earnings Results - MarketBeat

Feb 17, 2025

Alnylam Delivers a Big Q4 Earnings Beat - MSN

Feb 17, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 17, 2025

Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say - MSN

Feb 17, 2025

Alnylam Pharma: Hold Rating Due to Stable Financials and Uncertain Pipeline Prospects - TipRanks

Feb 17, 2025

Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - MSN

Feb 17, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Releases Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Feb 17, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat

Feb 16, 2025

Van ECK Associates Corp Purchases 10,419 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Feb 16, 2025

Savant Capital LLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat

Feb 16, 2025

Feb 15, 2025

Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates - MSN

Feb 15, 2025

Alnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansion - MSN

Feb 15, 2025

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN

Feb 15, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC - MarketBeat

Feb 15, 2025

Learn to Evaluate (ALNY) using the Charts - Stock Traders Daily

Feb 15, 2025

Feb 14, 2025

Royal Bank of Canada Reiterates "Outperform" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat

Feb 14, 2025

Alnylam Earnings: Strong Patient Uptake Drives Growth; Anticipating Approval of Amvuttra for ATTR-CM - Morningstar

Feb 14, 2025

Embrace the competition from China, says Maraganore - BioCentury

Feb 14, 2025

RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating - Marketscreener.com

Feb 14, 2025